IP Library Granted Patent US 8,445,429
Granted Patent B2
US 8,445,429 · App. 13/319,655 · Granted May 21, 2013

Lactoferrin and neuronal health and development in the infant gut

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,445,429
App. No.
13/319,655
Granted
May 21, 2013
Kind
B2
Abstract

The present invention relates generally to the field of neuronal health, neuronal protection and neuronal development. One embodiment of the present invention relates to a composition that can be used for the treatment or prevention of a delayed development of the enteric nervous system. Neuronal cells in the gut can be protected. Disorders linked to a delayed development of the enteric nervous system and/or to an impaired enteric nervous system can be treated or prevented by the administration of lactoferhn containing compositions.

Claims (18)

1. Ingestible composition comprising lactoferrin in a concentration of 0.1 g-100 g/100 kcal of the composition, the composition comprising a source of protein, a source of lipids, and a source of carbohydrates and having a form of an infant feeding formula, the source of protein present in an amount between 1.4 and 4.0 g/100 kcal of the composition, the composition comprising at least about 70 mg/L of total sialic acid, at least about 0.1% omega-3 fatty acid by weight of total fatty acids, and at least about 0.25% omega-6 fatty acids by weight of the total fatty acids, and the sialic acid is selected from the group consisting of 2-keto-5-acetamido-3,5-dideoxy-d-glycero-d-galactononulosonic acid (Neu5Ac), 2-keto-3-deoxy-d-glycero-d-galactonononic acid (KDN) and combinations thereof.

2. Composition according to claim 1 , wherein the lactoferrin is provided as a milk or whey fraction enriched in lactoferrin.

3. Composition according to claim 1 , wherein over 50% by weight of the protein source is whey protein.

4. Composition according to claim 1 , wherein the lipid source contributes between 30 to 55% of the total energy of the composition.

5. Composition according to claim 1 , wherein the lactoferrin is present in a concentration in the range of about 2 g-25 g per 100 kcal.

6. Composition according to claim 1 , wherein the composition is to be administered in an amount corresponding to an ingestion of at least 0.01 g lactoferrin per kg body weight per day.

7. A method for the promotion of the development of the enteric nervous system comprising administering a composition comprising Lactoferrin according to claim 1 to an individual in need of same.

8. A method for the repair of an impaired enteric nervous system comprising administering a composition comprising Lactoferrin according to claim 1 to an individual in need of same.

9. A method for treating disorders linked to a delayed development of the enteric nervous system, and/or an impaired enteric nervous system comprising administering a composition comprising Lactoferrin according to claim 1 to an individual in need of same.

10. Method in accordance with claim 9 , wherein the disorder is selected form the group consisting of a low digestive and/or absorptive capacity, gastrointestinal reflux, a slow intestinal transit, a weak intestinal barrier function, food intolerance, gut discomfort, and hard stools.

11. Method of claim 7 , wherein the individual is selected from the group consisting of mothers during pregnancy, mothers during lactation, premature or term born babies, infants, toddlers, children and teenagers.

12. Method of claim 8 , wherein the individual is selected from the group consisting of mothers during pregnancy, mothers during lactation, premature or term born babies, infants, toddlers, children and teenagers.

13. Method of claim 9 , wherein the individual is selected from the group consisting of mothers during pregnancy, mothers during lactation, premature or term born babies, infants, toddlers, children and teenagers.

14. Composition according to claim 1 , wherein the carbohydrate source contributes between 35 and 65% of the total energy of the composition.

15. Method of claim 7 , wherein the lactoferrin is present in the composition in a concentration of 2 g-25 g/100 kcal of the composition.

16. Method of claim 7 , wherein the composition is administered to provide at least 0.2 g lactoferrin per kg of body weight of the individual per day.

17. Method of claim 7 , wherein the composition is administered to provide at least 1 g lactoferrin per kg of body weight of the individual per day.

18. Method of claim 8 , wherein the lactoferrin is present in the composition in a concentration of 2 g-25 g/100 kcal of the composition.

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE PATENT NUMBER 16062921 PREVIOUSLY RECORDED ON REEL 049391 FRAME 0756. ASSIGNOR(S) HEREBY CONFIRMS THE PATENT NUMBER SHOULD HAVE BEEN 16062912. Recorded Jul 3, 2020
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 054082/0001 →
CORRECTIVE ASSIGNMENT TO CORRECT THE PATENT NUMBER 16062921 PREVIOUSLY RECORDED ON REEL 049391 FRAME 0756. ASSIGNOR(S) HEREBY CONFIRMS THE PATENT NUMBER SHOULD HAVE BEEN 16062912. Recorded Jul 3, 2020
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 054082/0165 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ENGLISH TRANSLATION TO SHOW THE FULL AND CORRECT NEW NAME IN SECTION 51. PREVIOUSLY RECORDED AT REEL: 049391 FRAME: 0756. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER. Recorded Jun 13, 2019
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 049853/0398 →
MERGER Recorded Jun 6, 2019
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 049391/0756 →